We are live on ! Find out more
INFI

Infinity Pharmaceuticals, Inc.

Delisted

INFI was delisted on the 13th of September, 2023.

45 hedge funds and large institutions have $32.2M invested in Infinity Pharmaceuticals, Inc. in 2020 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,600% more call options, than puts

Call options by funds: $81K | Put options by funds: $3K

28% more capital invested

Capital invested by funds: $25.1M → $32.2M (+$7.06M)

6% less funds holding

Funds holding: 4845 (-3)

18% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 11

50% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 6

Holders
45
Holders Change
-3
Holders Change %
-6.25%
% of All Funds
0.91%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
9
Reduced
11
Closed
6
Calls
$81K
Puts
$3K
Net Calls
+$78K
Net Calls Change
+$74K
Name Holding Trade Value Shares
Change
Change in
Stake
BI
1
BVF Inc
California
$20.4M
Vanguard Group
2
Vanguard Group
Pennsylvania
$2.71M
Renaissance Technologies
3
Renaissance Technologies
New York
$2.09M +$161K +156,295 +10%
BlackRock
4
BlackRock
New York
$1.14M +$59 +57 +0%
PIM
5
Platinum Investment Management
Australia
$1.08M
Acadian Asset Management
6
Acadian Asset Management
Massachusetts
$758K +$52.9K +51,482 +9%
BBA
7
Baker Bros. Advisors
New York
$679K
BCM
8
Bridgeway Capital Management
Texas
$491K
Geode Capital Management
9
Geode Capital Management
Massachusetts
$435K
Dimensional Fund Advisors
10
Dimensional Fund Advisors
Texas
$346K -$614K -597,526 -67%
Jacobs Levy Equity Management
11
Jacobs Levy Equity Management
New Jersey
$325K
BL
12
Bleichroeder LP
New York
$292K
Northern Trust
13
Northern Trust
Illinois
$195K -$2K -1,943 -1%
EWM
14
Evercore Wealth Management
New York
$167K
Qube Research & Technologies (QRT)
15
Qube Research & Technologies (QRT)
United Kingdom
$141K +$98.5K +95,860 +383%
OM
16
Opaleye Management
Massachusetts
$137K +$3.26M +3,171,800 New
California Public Employees Retirement System
17
California Public Employees Retirement System
California
$103K
Bank of New York Mellon
18
Bank of New York Mellon
New York
$81K -$1 -1 -0%
NC
19
NewSquare Capital
Pennsylvania
$81K
State Street
20
State Street
Massachusetts
$65K
Goldman Sachs
21
Goldman Sachs
New York
$64K +$55.9K +54,422 New
Russell Investments Group
22
Russell Investments Group
United Kingdom
$50K -$43 -42 -0.1%
T. Rowe Price Associates
23
T. Rowe Price Associates
Maryland
$46K
Morgan Stanley
24
Morgan Stanley
New York
$41K +$26.4K +25,695 +269%
Susquehanna International Group
25
Susquehanna International Group
Pennsylvania
$40K -$876 -853 -2%

INFI Hedge Fund Activity: Q3 2020 in Review

45 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q3 2020, worth a combined $32.2M — up 28% from $25.1M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of INFI and 3 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 9 added.

The largest buyer was Opaleye Management, opening a new position worth an estimated $3.26M. The largest seller was Dimensional Fund Advisors, cutting an estimated $614K.

  • 45 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q3 2020, down from 48 in Q2 2020.
  • Funds reported $32.2M of Infinity Pharmaceuticals, Inc. stock for Q3 2020, up 28% quarter-over-quarter.
  • 3 funds opened new Infinity Pharmaceuticals, Inc. positions in Q3 2020 and 6 closed out, a net change of -3 holders.
  • The largest Infinity Pharmaceuticals, Inc. buyer in Q3 2020 was Opaleye Management, an estimated $3.26M added.
  • The largest Infinity Pharmaceuticals, Inc. seller in Q3 2020 was Dimensional Fund Advisors, an estimated $614K sold.

Based on aggregated 13F filings for Q3 2020.